Health economic evaluation of bevacizumab for metastatic colorectal cancer
We have undertaken a model based analysis of the cost effectiveness of bevacizumab for first line treatment of metastatic colorectal cancer in Norway. We have investigated the effect of adding bevacizumab to standard chemotherapy. The analysis does have a considerable uncertainty, and the results sh...
| Otros Autores: | |
|---|---|
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Oslo :
Norwegian Knowledge Centre for the Health Services
2007.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009816712706719 |
